Targeting homologous recombination addicted tumors: challenges and opportunities

por Golan, Talia, Brody, Jonathan R.
Publicado 2020

Structural Implications for Selective Targeting of PARPs

por Steffen, Jamin D., Brody, Jonathan R., Armen, Roger S., Pascal, John M.
Publicado 2013

Metabolic Dependencies in Pancreatic Cancer

por Vaziri-Gohar, Ali, Zarei, Mahsa, Brody, Jonathan R., Winter, Jordan M.
Publicado 2018

Corrigendum: Metabolic Dependencies in Pancreatic Cancer

por Vaziri-Gohar, Ali, Zarei, Mahsa, Brody, Jonathan R., Winter, Jordan M.
Publicado 2019

Ultra-fast conductive media for RNA electrophoretic mobility shift assays

por Brown, Samantha Z, Agostini, Lebaron C, Thomsett, Henry L, Brody, Jonathan R
Publicado 2019

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms

por Chand, Saswati, O'Hayer, Kevin, Blanco, Fernando F., Winter, Jordan M., Brody, Jonathan R.
Publicado 2016

Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: Considerations from somatic mutations in microsatellite unstable (MSI) gastr...

por van der Heijden, Michiel S, Brody, Jonathan R, Elghalbzouri-Maghrani, Elhaam, Zdzienicka, Malgorzata Z, Kern, Scott E
Publicado 2006

BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer

por Pishvaian, Michael J, Biankin, Andrew V, Bailey, Peter, Chang, David K, Laheru, Daniel, Wolfgang, Christopher L, Brody, Jonathan R
Publicado 2017

Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry

por Yeo, Theresa P., Lavu, Harish, Nevler, Avinoam, Brumbaugh, Jennifer, Vicchairelli, Dominique, Winter, Jordan M., Brody, Jonathan R., Yeo, Charles J.
Publicado 2018

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

por Valsecchi, Matias E, Holdbrook, Thomas, Leiby, Benjamin E, Pequignot, Edward, Littman, Susan J, Yeo, Charles J, Brody, Jonathan R, Witkiewicz, Agnieszka K
Publicado 2012

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment

por Rao, Shruti, Beckman, Robert A., Riazi, Shahla, Yabar, Cinthya S., Boca, Simina M., Marshall, John L., Pishvaian, Michael J., Brody, Jonathan R., Madhavan, Subha
Publicado 2016

Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedure

por Bauer, Tyler M., Dhir, Teena, Strickland, Adam, Thomsett, Henry, Goetz, Austin B., Cannaday, Shawnna, Brody, Jonathan R., Pishvaian, Michael J., Yeo, Charles J.
Publicado 2018

HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms

por Jain, Aditi, McCoy, Matthew, Coats, Carolyn, Brown, Samantha Z., Addya, Sankar, Pelz, Carl, Sears, Rosalie C., Yeo, Charles J., Brody, Jonathan R.
Publicado 2022

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

por Witkiewicz, Agnieszka K., Borja, Nicholas A., Franco, Jorge, Brody, Jonathan R., Yeo, Charles J., Mansour, John, Choti, Michael A., McCue, Peter, Knudsen, Erik S.
Publicado 2015

WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner

por Lal, Shruti, Zarei, Mahsa, Chand, Saswati N., Dylgjeri, Emanuela, Mambelli-Lisboa, Nicole C., Pishvaian, Michael J., Yeo, Charles J., Winter, Jordan M., Brody, Jonathan R.
Publicado 2016

Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarci...

por Ponzini, Francesca M, Schultz, Christopher W, Leiby, Benjamin E, Cannaday, Shawnna, Yeo, T, Posey, James, Bowne, Wilbur B, Yeo, Charles, Brody, Jonathan R, Lavu, Harish, Nevler, Avinoam
Publicado 2023

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2

por Nevler, Avinoam, Muller, Alexander J, Cozzitorto, Joseph A, Goetz, Austin, Winter, Jordan M, Yeo, Theresa P, Lavu, Harish, Yeo, Charles J, Prendergast, George C, Brody, Jonathan R
Publicado 2018

A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma

por Tesfaye, Anteneh A., Wang, Hongkun, Hartley, Marion L., He, Aiwu Ruth, Weiner, Louis, Gabelia, Nina, Kapanadze, Lana, Shezad, Muhammad, Brody, Jonathan R., Marshall, John L., Pishvaian, Michael J.
Publicado 2019

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy

por Huang, Yu-Hung, Peng, Weidan, Furuuchi, Narumi, DuHadaway, James B., Jimbo, Masaya, Pirritano, Andrea, Dunton, Charles J., Daum, Gary S., Leiby, Benjamin E., Brody, Jonathan R., Sawicki, Janet A.
Publicado 2016

Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis

por Blanco, Fernando F., Preet, Ranjan, Aguado, Andrea, Vishwakarma, Vikalp, Stevens, Laura E., Vyas, Alok, Padhye, Subhash, Xu, Liang, Weir, Scott J., Anant, Shrikant, Meisner-Kober, Nicole, Brody, Jonathan R., Dixon, Dan A.
Publicado 2016